September 14, 2021

Plenary Session 1: Epidemiology and Cancer Prevention
Session Chair: Elizabeth M. Swisher, University of Washington, Seattle, Washington

Session Introduction

Opportunistic salpingectomy: one decade later
Jessica N. McAlpine, University of British Columbia, Vancouver, BC, Canada

Ovarian cancer detection and risk assessment using high fidelity sequencing
Rosana Risques, University of Washington, Seattle, WA

PALB2, ovarian cancer gene?
Barbara Norquist, University of Washington, Seattle, WA

Endometriosis and ovarian cancer risk
Holly Harris, Fred Hutchinson Cancer Center, Seattle, WA

Panel Discussion

Plenary Session 2: Ovarian Cancer Genetics, Epigenetics, and Evolution
Session Chair: Benjamin G. Neel, NYU Langone Health Perlmutter Cancer Center, New York, New York

Session Introduction

Longitudinal, multi-region assessment of tumor evolution in patients with high-grade serous ovarian cancer
Sampsa Hautaniemi, University of Helsinki, Helsinki, Finland

Rewiring of transcriptional circuits during high-grade serous ovarian cancer development
Kate Lawrenson, Cedars-Sinai Medical Center, Los Angeles, CA

Genomic and immunological features of high-grade serous ovarian cancer in long-term survivors
Dale W. Garsed, Peter MacCallum Cancer Centre, Melbourne, Australia

Panel Discussion

September 15, 2021

Plenary Session 3: DNA Damage and Replication Stress
Session Chair: Kunle Odunsi, University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

Session Introduction
Overcoming PARP inhibitor resistance  
Alan D’Andrea, Dana-Farber Cancer Institute, Boston, MA

USP1-trapping lesions as a source of DNA replication stress and genomic instability  
Tony Huang, NYU Langone Health Perlmutter Cancer Center, New York, NY

The role of BRCA1 mutations and therapy resistance  
Neil Johnson, Fox Chase Cancer Center, Philadelphia, PA

The success and challenges of introducing PARP inhibitors into the therapy of ovarian cancer  
Jonathan A. Ledermann, UCL Cancer Institute at University College London, London, United Kingdom

Panel Discussion

Plenary Session 4: Immunology and Tumor Microenvironment
Session Chair: Frances R. Balkwill, Barts Cancer Institute, Queen Mary University of London, London, England

Session Introduction

Single-cell spatial proteomic profiling of the tumor microenvironment for biomarker discovery in ovarian cancer  
Anniina Färkkilä, University of Helsinki, Helsinki, Finland

Engineering adoptive T cell therapy to overcome immune suppression in ovarian cancer  
Kristin G. Anderson, Fred Hutchinson Cancer Center, Seattle, WA

Mechanisms of tumor immunogenicity and anti-tumor immunity in ovarian cancer  
Denarda Dangaj, Ludwig Institute for Cancer Research UNIL CHUV, Lausanne, Switzerland

Mutational processes as determinants of immunophenotypes in ovarian cancer  
Sohrab Shah, Memorial Sloan Kettering Cancer Center, New York